#dc comics#dc#batman#bruce wayne#batfamily#batfam#dick grayson#dc fanart#tim drake
seen from Belarus
seen from Poland
seen from China
seen from United States
seen from Malaysia
seen from Indonesia
seen from China
seen from China
seen from China
seen from Kosovo
seen from Kosovo
seen from China
seen from United States
seen from China
seen from Malaysia
seen from United States
seen from China
seen from Singapore
seen from China
seen from Malaysia
guys im not checking my phone for like an hour SPAM NE GUYS SOSHKS
Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
High expression of PSMA in prostate cancer makes it an attractive target for imaging and therapy. The left image shows a Prostascint scan (indium-111-capromab, an anti-PSMA antibody) in a patient with metastatic prostate cancer (black arrow). The FDA recently approved 2 PET radiopharmaceuticals that bind the extracellular domain of PSMA (Ga-68-gozetotide and F-18-piflufolostat). The right image shows an F-18-piflufolostat scan. The superior signal-to-noise and resolution of PET allow for detection of the tiny metastatic nodes seen in the pelvis.
Image credit
Left: Bhargava et al. Am. Jour. Nucl. Med. Mol. Imag. 2012.
Right: Dr. Thomas Anderson
Clinical trials are also underway for PSMA-targeted therapy with alpha-emitting radionuclides. Alpha particles are much more energetic and thus cause more localized damage than beta particles. They do not travel as far in tissue, so they tend to have less toxicity. Image shows a patient with metastatic prostate cancer who had excellent response after 2 cycles of actinium-225-PSMA targeted alpha therapy (TAT). Reference: Zacherl et al. J. Nucl. Med. 2021, 62, 669-674.
#TeachingRounds#FOAMed#FOAMRad#Radiology#NuclearMedicine#PETCT
#Theransotics#NucMed#PSMA#radioligandtherapy#urology#oncology#alphatherapy
PSMA PET can also help DOWNSTAGE some patients. This is an example of a patient who had an enlarged retroperitoneal lymph node (red arrow). Based on CT alone, this is highly suspicious for metastasis, however, on the PET scan this is not PSMA-positive and as such is not a metastasis (note the primary tumor is PSMA-positive - blue arrow). The patient was thus staged as N0M0. Image credit: Novartis.
PSMA is a molecule; it is a receptor that is overexpressed in patients with prostate cancer. Practically all prostate cancer patients will e
PSMA is a molecule; it is a receptor that is overexpressed in patients with prostate cancer. Practically all prostate cancer patients will express PSMA. Know more at nuclearmedicinetherapy.in
Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
Castrate Resistant Prostate Cancer Treatment Ac225 PSMA Therapy Targeted Alpha Therapy
For CRPC patients receiving Ac225 PSMA Therapy, there cycles of treatments at intervals of two months are administered. And depending upon the response to therapy, further salvage cycles may be given.
know more at:
For CRPC patients receiving Ac225 PSMA Therapy, there cycles of treatments at intervals of two months are administered. And depending upon t
Actinium and Lutetium PSMA Therapy Explored by Dr. Ishita B Sen
Join us for an in-depth discussion as Dr. Ishita B Sen unlocks the potential of Actinium and Lutetium PSMA therapy, offering new hope in the fight against cancer.
Read More at:
PSMA is a membrane glycoprotein which is expressed on the Prostate Cancer Cells. It expressed on normal Prostate Cells also but in Prostate
Lu177 PSMA therapy is a type of cancer treatment that uses a radioactive isotope called Lutetium-177 (Lu177) to selectively target and destroy cancer cells in the body. Our studies have shown that Lu177 PSMA therapy can improve survival and quality of life for patients with advanced prostate cancer. Know more at nuclearmedicine Therapy
